Aero, a decentralized exchange formed by merging Aerodrome and Velodrome, quickly achieved top rankings on the Base and Optimism networks shortly after its October 21 launch. The platform is rolling out across seven networks, including Ethereum mainnet, Robinhood Chain, Ink, OP Mainnet, Arc, and Arbitrum, which collectively handle about $120 billion in monthly decentralized exchange volume. While Aero's exact trading volume remains undisclosed, its prominent chart positions highlight strong early adoption. This multi-network presence positions Aero as a significant player in decentralized trading across major blockchain ecosystems.
Aero's rapid rise on Base and Optimism networks comes as Pluang data shows a challenging day for cryptocurrencies overall. For readers following crypto markets, here is Pluang's market snapshot as of Oct 24, 2026 20:01 WIB: out of 50 major cryptocurrencies priced on Pluang, only 5 rose while 43 fell. Notable movers include COTI at Rp196 with a 7.12% decline and 84% sell order activity, ATOM at Rp30,122 down 7.05% with balanced order activity, and SNX at Rp3,660 down 5.18% but with 100% buy order activity and a typical hold time of 70 days.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
